Radiation Therapy News and Research

RSS
Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Initiation of Phase I/IIa clinical trial of IL-7 announced

Initiation of Phase I/IIa clinical trial of IL-7 announced

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

RaySearch Laboratories' interim report for the period January 1 – September 30, 2009

RaySearch Laboratories' interim report for the period January 1 – September 30, 2009

iCAD and AdMeTech Foundation sign a strategic partnership agreement

iCAD and AdMeTech Foundation sign a strategic partnership agreement

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

Study to test anti-tumor effects of AEOL 10150 initiated

Study to test anti-tumor effects of AEOL 10150 initiated

New insights into cells' reaction to DNA damage

New insights into cells' reaction to DNA damage

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

3-D software uses real patient data; offers virtual reality technology for doctors and students

3-D software uses real patient data; offers virtual reality technology for doctors and students

Men more likely to abandon partners diagnosed with cancer

Men more likely to abandon partners diagnosed with cancer

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

SAVI reaches a major milestone in breast brachytherapy

SAVI reaches a major milestone in breast brachytherapy

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

Landauer announces GPS acquisition

Landauer announces GPS acquisition

St. Jude Children's Research Hospital patients to receive proton therapy at the UF Proton Therapy Institute

St. Jude Children's Research Hospital patients to receive proton therapy at the UF Proton Therapy Institute

PET scanning emerges as an important tool in the evaluation of lung cancer

PET scanning emerges as an important tool in the evaluation of lung cancer

American Shared Hospital Services reports financial results for the third quarter of 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.